CorEVITAS Abs 1499 #ACRbest #ACR22 cycling to a second line TNFi provides limited benefits to pts with AxSpA who discontinued a first line TNFi. @RheumNow https://t.co/fKDa5kPfXN https://t.co/CtMCj2Ihgc

• The Impact of Cycling Among Tumor Necrosis Factor Inhibitors on Disease Control…

Papagoras et al. Serum GM-CSF increased in AxSpA and persists despite TNFi. Are we going to have a trial of mavrilimumab in AxSpA then? @RheumNow #ACR22 Abstr#1156 https://t.co/wCFsY9nC1p https://t.co/lrQQ7tIX4x

• Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in…

Lifestyle modifications can affect tx response with TNFi in axSpA! Accdg to this study fr Prof GJones, ✳️Smokers, overwt & obese pts are ⬇️ likely to achieve treatment response to TNFi vs. nonsmokers & normal wt pts Smoking cessation, wt mgt is key! #ACR22 @RheumNow ABST#1510 https://t.co/PBFcj6zKVD

Once again, high BMI and smoking associated with substantial decrease in TNFi response for treatment of axSpA. Easier said than done however. How are you helping pts lose weight or stop smoking? Abs#1510 @RheumNow #ACR22 https://t.co/ircLkuXhCs

Dr PMease et al looked into impact of TNFi cycling in their #axSpA cohort: 💠After 6mos on 2nd TNFi, only 15% had ASDAS-LDA, 7% MCID in ASDAS, 8% >50% improvement 💠Cycling to 2nd TNFi limited benefits ⬇️sample size, worth further investigation #ACR22 @RheumNow ABST#1499 https://t.co/OVJxezdipW

#abs0948 #acr22 @rheumnow perception on fertility&ART in pts w/rheum Dx: 60% believe their Dx affects fertility/25% believe meds do: most cited MTX, steroids, TNFi, HCQ, NSAIDs. 92% heard of ART but unsure if safe or successful w/their Dx. Hx of infertility 29%/only 52% go w/ART https://t.co/lmaM773gP5

Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE https://t.co/7bCkfk7EYY

Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY

• Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necr…

Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4

• COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy ver…

Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk

• Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatm…